Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harald Hampel

Showing results (31-40 of 411) with videos related to

Pageof 42
Sort By:
Nature Reviews. Neurology|February 17, 2010
Cerebrospinal fluid and plasma biomarkers in Alzheimer diseaseKaj Blennow, Harald Hampel, Michael Weiner, et al.
Dialogues in Clinical Neuroscience|July 10, 2009
Biological markers for early detection and pharmacological treatment of Alzheimer's diseaseHarald Hampel, Karl Broich, Yvonne Hoessler, et al.
Progress in Neurobiology|June 30, 2012
Blood and plasma-based proteomic biomarker research in Alzheimer's diseaseSimone Lista, Frank Faltraco, David Prvulovic, et al.
Current Pharmaceutical Design|February 26, 2013
Diffusion tensor imaging to determine effects of antidementive treatment on cerebral structural connectivity in Alzheimer's diseaseIngo Kilimann, Yuttachai Likitjaroen, Harald Hampel, et al.
Progress in Neurobiology|June 30, 2009
Assessing neuronal networks: understanding Alzheimer's diseaseArun L W Bokde, Michael Ewers, Harald Hampel
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|September 22, 2007
Pharmacological treatment of Alzheimer's dementia: state of the art and current dilemmasMuamer Omerovic, Harald Hampel, Stefan J Teipel, et al.
Current Pharmaceutical Design|February 26, 2013
Imaging epigenetics in Alzheimer's diseaseSimone Lista, Francesco G Garaci, Nicola Toschi, et al.
International Psychogeriatrics|August 19, 2007
Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementiaStefan Lorenzl, Katharina Buerger, Harald Hampel, et al.
Expert Review of Proteomics|March 11, 2017
Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer's disease and other neurodegenerative diseasesFilippo Baldacci, Simone Lista, Enrica Cavedo, et al.
Frontiers in Neurology|August 31, 2018
Basal Forebrain Volume, but Not Hippocampal Volume, Is a Predictor of Global Cognitive Decline in Patients With Alzheimer's Disease Treated With Cholinesterase InhibitorsStefan J Teipel, Enrica Cavedo, Harald Hampel, et al.
Pageof 42

Showing results (31-40 of 411) with videos related to

Sort By:
Pageof 42
Nature Reviews. Neurology|February 17, 2010
Cerebrospinal fluid and plasma biomarkers in Alzheimer diseaseKaj Blennow, Harald Hampel, Michael Weiner, et al.
Dialogues in Clinical Neuroscience|July 10, 2009
Biological markers for early detection and pharmacological treatment of Alzheimer's diseaseHarald Hampel, Karl Broich, Yvonne Hoessler, et al.
Progress in Neurobiology|June 30, 2012
Blood and plasma-based proteomic biomarker research in Alzheimer's diseaseSimone Lista, Frank Faltraco, David Prvulovic, et al.
Current Pharmaceutical Design|February 26, 2013
Diffusion tensor imaging to determine effects of antidementive treatment on cerebral structural connectivity in Alzheimer's diseaseIngo Kilimann, Yuttachai Likitjaroen, Harald Hampel, et al.
Progress in Neurobiology|June 30, 2009
Assessing neuronal networks: understanding Alzheimer's diseaseArun L W Bokde, Michael Ewers, Harald Hampel
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|September 22, 2007
Pharmacological treatment of Alzheimer's dementia: state of the art and current dilemmasMuamer Omerovic, Harald Hampel, Stefan J Teipel, et al.
Current Pharmaceutical Design|February 26, 2013
Imaging epigenetics in Alzheimer's diseaseSimone Lista, Francesco G Garaci, Nicola Toschi, et al.
International Psychogeriatrics|August 19, 2007
Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementiaStefan Lorenzl, Katharina Buerger, Harald Hampel, et al.
Expert Review of Proteomics|March 11, 2017
Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer's disease and other neurodegenerative diseasesFilippo Baldacci, Simone Lista, Enrica Cavedo, et al.
Frontiers in Neurology|August 31, 2018
Basal Forebrain Volume, but Not Hippocampal Volume, Is a Predictor of Global Cognitive Decline in Patients With Alzheimer's Disease Treated With Cholinesterase InhibitorsStefan J Teipel, Enrica Cavedo, Harald Hampel, et al.
Pageof 42